Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
株式のランク #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
株価
$0.00244926
時価総額
$51.67K
変化(1日)
5.88%
変化(1年)
110.15%
GB
取引 Nuformix plc (NFX)

カテゴリー

Nuformix plc(NFX)の収益
Sep 2025 時点の収益 TTM: 0.00
Nuformix plc の最新の財務報告によると、現在の収益 (TTM) は 0.00 です。2024 年には 0.00 の収益があり、これは 2023 年の 0.00 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Nuformix plc の収益履歴(2014 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 $65.73K -75.61%
2021 $269.56K -59.39%
2020 $663.79K -16.44%
2019 $794.35K 3,678.32%
2018 $21.02K 0.00%
2017 0.00 -100.00%
2016 $872.91K 181.15%
2014 $310.47K 0.00%
同業他社の収益
企業 収益 収益の差
$48.44B -
DK
$12.04B -
US
$14.34B -
US
$9.08B -
BE
$15.70B -
AU